Opinion

Video

Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
      Anne Schuckman, MD, highlights promising new developments in NMIBC
      Anne Schuckman, MD, highlights promising new developments in NMIBC
      Howard Goldman, MD, discusses development of the Glean Urodynamics System
      Howard Goldman, MD, discusses development of the Glean Urodynamics System
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
      Vignesh Packiam, MD, on choosing between options in NMIBC
      Vignesh Packiam, MD, on choosing between options in NMIBC
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      4 experts in this video
      Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Related Content
      FDA grants RMAT designation to detalimogene voraplasmid for high-risk NMIBC
      June 25th 2025

      FDA grants RMAT designation to detalimogene voraplasmid for high-risk NMIBC

      Hannah Clarke
      Detalimogene is currently under evaluation in the pivotal phase 1/2 LEGEND trial.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance
      June 16th 2025

      From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance

      Anne K. Schuckman, MD Hannah Clarke
      Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
      June 12th 2025

      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC

      Hannah Clarke
      The approval is supported by findings from the phase 3 ENVISION trial.
      Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients
      June 11th 2025

      Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients

      Cleveland Clinic
      Glean™ Urodynamics System developed by Bright Uro based on foundational technology created at Cleveland Clinic; Device received FDA clearance earlier this year
      © 2025 MJH Life Sciences

      All rights reserved.